Global update on defining and treating high-risk localized prostate cancer with leuprorelin: An Asian perspective

BJU International

Volumn 99, Issue SUPPL. 1, 2007, Pages 6-9

  Mizokami, Atsushi ^a   Ueno, Satoshi ^a   Fukagai, Takashi ^b   Ito, Kazuto ^c   Ehara, Hidetoshi ^d   Kinbara, Hiroyuki ^e   Origasa, Hideki ^f   Usami, Michiyuki ^g   Namiki, Mikio ^a   Akaza, Hideyuki ^h  

^a KANAZAWA UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY   (Japan)

^c GUNMA UNIVERSITY   (Japan)

^d GIFU UNIVERSITY   (Japan)

^e MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f UNIVERSITY OF TOYAMA   (Japan)

^g OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^h UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Asia; High risk; Hormone therapy; Leuprorelin; Prostate cancer; Quality of life

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN AGONIST; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; ASIA; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTERMETHOD COMPARISON; JAPAN; MEDICAL DECISION MAKING; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION DOSE; RISK ASSESSMENT; SEXUAL FUNCTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE-FREE SURVIVAL; HUMANS; JAPAN; LEUPROLIDE; MALE; MULTICENTER STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 33845656043     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06592.x     Document Type: Conference Paper

References (8)

1. Cooperberg MR, Grossfeld GD, Lubeck DP, Carroll PR. National practice patterns and time trends in androgen ablation for localized prostate cancer. J Natl Cancer Inst 2003; 95: 981-9
2. Peschel RE, Colberg JW. Surgery, brachytherapy, and external-beam radiotherapy for early prostate cancer. Lancet Oncol 2003; 4: 233-41
3. Cancer Registration Committee of the Japanese Urological Association. Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 2005; 12: 46-61
4. Akaza H. Trends in primary androgen depletion therapy for patients with localized and locally advanced prostate cancer: Japanese perspective. Cancer Sci 2006; 97: 243-7
5. Ueno S, Namiki M, Akaza H et al. The efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer - the results of a retrospective multi-center study in prostate cancer patient. Int J Urol 2006; in press
6. Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103-6
7. Shigehara K, Mizokami A, Komatsu K, Koshida K, Namiki M. Four year clinical statistics of iridium-192 high dose rate brachytherapy. Int J Urol 2006; 13: 116-21
8. Morley JE, Charlton E, Patrick P et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49: 1239-42